Biomarkers and Surrogate Endpoints for Normal-Tissue Effects of Radiation Therapy: The Importance of Dose-Volume Effects

Søren M. Bentzen, Matthew Parliament, Joseph O. Deasy, Adam Dicker, Walter J. Curran, Jacqueline P. Williams, Barry S. Rosenstein

Research output: Contribution to journalArticlepeer-review

68 Scopus citations

Abstract

Biomarkers are of interest for predicting or monitoring normal tissue toxicity of radiation therapy. Advances in molecular radiobiology provide novel leads in the search for normal tissue biomarkers with sufficient sensitivity and specificity to become clinically useful. This article reviews examples of studies of biomarkers as predictive markers, as response markers, or as surrogate endpoints for radiation side effects. Single nucleotide polymorphisms are briefly discussed in the context of candidate gene and genomewide association studies. The importance of adjusting for radiation dose distribution in normal tissue biomarker studies is underlined. Finally, research priorities in this field are identified and discussed.

Original languageEnglish
Pages (from-to)S145-S150
JournalInternational Journal of Radiation Oncology Biology Physics
Volume76
Issue number3 SUPPL.
DOIs
StatePublished - 1 Mar 2010
Externally publishedYes

Keywords

  • Biomarkers
  • Dose distribution
  • Normal tissue effects
  • Predictive factors
  • Radiogenomics
  • Single nucleotide polymorphisms
  • Surrogate endpoints
  • Toxicity

Fingerprint

Dive into the research topics of 'Biomarkers and Surrogate Endpoints for Normal-Tissue Effects of Radiation Therapy: The Importance of Dose-Volume Effects'. Together they form a unique fingerprint.

Cite this